Skip to main contentSkip to navigationSkip to search

News and Media

Curasight is committed to improving both diagnosis and treatment options for patients with certain types of cancer.

Our innovative theranostic platform, uPAR, allows us to more accurately characterize the type and stage of tumors using intelligent cancer imaging (uTRACE®) and with that knowledge, develop a more targeted, gentle and efficient approach to treatment (uTREAT®).

See our latest news releases & events, sign up to receive alerts and get answers to our most frequently asked questions.

Curasight A/S presents at Økonomisk Ugebrev Life Science Investor Conference in Copenhagen 20 October 2021

Curasight A/S presents at BioStock Life Science Summit 20 October 2021

CEO Ulrich Krasilnikoff presents Curasight at the spring edition of BioStock Life Science Summit, May 2021

CEO Ulrich Krasilnikoff and CSO Andreas Kjær present the company at Erik Penser Bank's Theme Day: Medical Imaging & Diagnostics, May 2021

Latest Press Releases

The subscription period in Curasight’s rights issue begins today

February 23, 2024
 | Regulatory

Curasight publishes information memorandum in connection with forthcoming rights issue

February 22, 2024
 | Regulatory

Annual Report for the fiscal year 2023

February 22, 2024
 | Regulatory